Treace Medical Concepts (TMCI) Common Equity (2020 - 2026)

Treace Medical Concepts' Common Equity history runs 7 years deep, the most recent figure standing at $77.2 million for Q1 2026.

• Quarterly Common Equity fell 26.72% year-over-year to $77.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.2 million (down 26.72% YoY) and the FY2025 annual result came in at $87.3 million, down 22.64% from the prior year.
• Common Equity was $77.2 million for Q1 2026 at Treace Medical Concepts, down from $87.3 million in the prior quarter.
• Across five years, Common Equity topped out at $157.6 million in Q1 2023 and bottomed at $60.5 million in Q4 2022.
• A 5-year average of $104.6 million and a median of $104.9 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 12792.69% in 2022, while the deepest fall reached 36.12% in 2022.
• Treace Medical Concepts' Common Equity stood at $60.5 million in 2022, then jumped by 127.89% to $137.9 million in 2023, then decreased by 18.16% to $112.9 million in 2024, then declined by 22.64% to $87.3 million in 2025, then retreated by 11.61% to $77.2 million in 2026.
• Business Quant data shows TMCI's Common Equity at $77.2 million in Q1 2026, $87.3 million in Q4 2025, and $89.2 million in Q3 2025.